You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The firm said total revenues fell to $424.0 million from $461.4 million in the first quarter of 2019, below analysts' consensus estimate of $444.4 million.
Bio-Rad said it is withdrawing its previously issued annual revenue guidance given the uncertainties regarding the duration and impact of the COVID-19 pandemic.
Researchers found that 61 percent of patients they analyzed carried germline pathogenic or likely pathogenic variants in candidate cancer predisposition genes.
The researchers said the findings underscore the need to study disease variants in a range of ancestral backgrounds.
Research institutions in the US and Europe will lead the studies, which will explore different aspects of COVID-19 such as host immune response.
The partners aim to identify signatures to predict the severity of disease in those infected and determine how patients will respond to therapies.
The researchers used a yeast-based synthetic genomics platform to engineer and resurrect chemically synthesized clones of the SARS-CoV-2 virus in only a week.
The effort, called SPHERES, aims to monitor changes in the virus to support public health research and diagnostic and therapeutic development.
Using protein interaction experiments, researchers identified agents that could disrupt SARS-CoV-2 and human proteins that bind to each other.
The funding, provided by the Chan Zuckerberg Initiative, will help test and study the Bay Area population in general as well as healthcare workers in particular.
Waters posted revenues of $464.9 million for the quarter as the SARS-CoV-2 pandemic drove a drop in sales globally, including a 45 percent decline in China.
Researchers combined genome-wide association and transcriptome study data to uncover cell types affected by complex brain disorders, including Parkinson's disease.
The San Diego-based genome mapping firm's share price fell below $1.00 for 30 consecutive days, triggering a noncompliance notification from Nasdaq.
Data collected from volunteers will be used in a genome-wide association study to better understand COVID-19.
These cells in the nose may serve as the virus entry point, according to an analysis of a single-cell RNA sequencing dataset spanning multiple tissue types.
The team, which was led by founders of the mass spec firm Purspec, demonstrated the ability of the instrument to quantify levels of the cancer marker Met.
The researchers studied the admixture of humans and Neanderthals using 14 million archaic chromosome fragments detected in whole genomes from 27,566 Icelanders.
Researchers described ancestry patterns, apparent population interactions, and genetic turnover during the late Neolithic and early Bronze Age.
With the help of Bionano Genomics, Genoox, Rescale, and Amazon, the investigators aim to study 1,000 patients with SARS-CoV-2 to better understand the disease.
Single-cell and single-molecule proteomics tools developed for the immuno-oncology market are proving useful for studying the immune response in COVID-19.
The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.
In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.